PUBLISHER: IMARC | PRODUCT CODE: 1422960
PUBLISHER: IMARC | PRODUCT CODE: 1422960
The global transcatheter pulmonary valve market size reached US$ 88.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 181.1 Million by 2032, exhibiting a growth rate (CAGR) of 8.06% during 2024-2032. The increasing incidence of various cardiovascular diseases (CVDs), extensive research and development (R&D) activities, and the rising geriatric population represent some of the key factors driving the market.
A transcatheter pulmonary valve refers to an artificial valve made from cow, pig, or human heart tissue. It is widely used to replace leaky or narrowed pulmonary valves to improve blood flow, with fewer incisions and faster recovery than open surgery. These valves are inserted through a thin, flexible tube (catheter) into a large blood vessel involving a minimally invasive (MI) procedure. Transcatheter pulmonary valve replacement involves less pain and a shorter recovery period and helps in improving symptoms while lowering the risk of medical complications. It also helps to restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. As a result, these valves find extensive applications in cardiac anomaly, pulmonary regurgitation, atresia, stenosis, and truncus arteriosus.
The rising incidences of various cardiovascular diseases (CVDs), such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases across the globe, are among the key factors driving the market growth. In line with this, the rising geriatric population and increasing prevalence of degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation are favoring the market growth. Moreover, the widespread product adoption in the treatment of pediatric transcatheter pulmonary is contributing to the market growth. This can be primarily attributed to the increasing frequency of pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders, which is facilitating the product adoption as an effective treatment option. Apart from this, the integration of artificial intelligence (AI) in the transcatheter pulmonary valve replacement (TPVR) procedure, as it assists in pre-procedural planning, identifying risk factors, and enhancing diagnosis and clinical decision-making, is providing an impetus to the market growth. Additionally, the increasing demand for balloon-expanded technology as it involves a faster and simpler process and offers high accuracy and precision of the result is positively influencing the market growth. Besides this, the launch of the hydra aortic valve, which is a self-expanding supra-annular aortic system made of nitinol that allows precise placement of the valve and ensures orthotopic deployment, is propelling the market growth. Other factors, including growing demand for innovative heart valves, an increasing number of hypertension cases, escalating growth in the healthcare industry, rising expenditure capacities of consumers, extensive research and development (R&D) activities, and the implementation of various government initiatives to develop efficient transcatheter pulmonary valves, are anticipated to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global transcatheter pulmonary valve market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, raw material, application, and end user.
Balloon-Expanded Transcatheter Valve
Self-Expanded Transcatheter Valve
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the technology. This includes balloon-expanded transcatheter valve and self-expanded transcatheter valve. According to the report, balloon-expanded transcatheter valve represented the largest segment.
Tissue Engineered
Synthetic
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the raw material. This includes tissue engineered and synthetic. According to the report, tissue engineered represented the largest segment.
Tetralogy of Fallot
Cardiac Anomaly
Pulmonary Atresia
Pulmonary Stenosis
Pulmonary Regurgitation
Truncus Arteriosus
Others
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the application. This includes tetralogy of fallot, cardiac anomaly, pulmonary atresia, pulmonary stenosis, pulmonary regurgitation, truncus arteriosus, and others. According to the report, tetralogy of fallot represented the largest segment.
Adult
Pediatric
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the end user. This includes adult and pediatric. According to the report, adult represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others);Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for transcatheter pulmonary valve. Some of the factors driving the North America transcatheter pulmonary valve market included the rising geriatric population, growing demand for innovative heart valves, and various technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter pulmonary valve market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Artivion Inc., Boston Scientific Corporation, Braile Biomedica, Colibri Heart Valve LLC, Edwards Lifesciences Corporation, JenaValve Technology Inc., Labcor Laboratorios Ltda., Medtronic plc, Venus Medtech (Hangzhou) Inc., etc.